Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
According to Nyxoah S.A.'s latest financial reports the company's current revenue (TTM) is $4.35 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
---|---|---|---|---|---|
2023 | $4.35 M | $2.69 M | $-43,286,000 | $-44,657,000 | $-43,212,000 |
2022 | $3.08 M | $1.93 M | $-27,887,000 | $-30,056,000 | $-31,225,000 |
2021 | $852 K | $549 K | $-24,580,000 | $-24,639,000 | $-27,619,000 |
2020 | $69 K | $39 K | $-10,604,000 | $-12,152,000 | $-12,245,000 |
2019 | $ | $-433,000 | $-6,650,000 | $-7,185,000 | $-7,255,000 |
2018 | $ | $-2,523,000 | $-8,835,000 | $-9,038,000 | $-9,079,000 |
2017 | $ | $-2,110,000 | $-10,119,000 | $-10,334,000 | $-10,371,000 |